Get the Stockscreener App
8.05
0.74%
-0.06
Neuphoria Therapeutics Inc stock is traded at $8.05, with a volume of 22,525.
It is down -0.74% in the last 24 hours and up +14.67% over the past month.
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
See More
Previous Close:
$8.11
Open:
$8
24h Volume:
22,525
Relative Volume:
0.77
Market Cap:
$15.13M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.29%
1M Performance:
+14.67%
6M Performance:
+51.89%
1Y Performance:
+0.00%
1-Day Range:
$7.78
$8.1384
1-Week Range:
$7.78
$8.90
52-Week Range:
$2.90
$12.55
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
8.05 | 15.25M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Key metrics from Neuphoria Therapeutics Inc.’s quarterly dataMarket Liquidity and Price Flow Analysis - Newser
Real time scanner hits for Neuphoria Therapeutics Inc. explainedHigh Return Idea With Technical Filter - Newser
Published on: 2025-08-01 18:37:53 - metal.it
What MACD and RSI say about Neuphoria Therapeutics Inc.RSI and MACD Signal Summary with Trends - Newser
Analyzing drawdowns of Neuphoria Therapeutics Inc. with statistical toolsMachine Learning Stock Movement Detector - Newser
Heatmap analysis for Neuphoria Therapeutics Inc. and competitorsPortfolio Risk Distribution Analysis Tool - Newser
What makes Neuphoria Therapeutics Inc. stock attractive to long term investorsBuy Point Strategy with Profit Protection - Newser
How does Neuphoria Therapeutics Inc. compare to its industry peersSwing Trade Forecasts For Smart Trading - jammulinksnews.com
Combining machine learning predictions for Neuphoria Therapeutics Inc.Free Smart Money Tracking Signal Generator - Newser
Why is Neuphoria Therapeutics Inc. stock attracting strong analyst attentionDaily Trading Outlook With Proven Results - jammulinksnews.com
Competitive Positioning of Neuphoria Therapeutics Inc.: Is It Leading or LaggingFree Pattern Alert With ROI Driven Strategy - Newser
Neuphoria Therapeutics Inc. stock retracement – recovery analysisQuarterly Investment Outlook and Key Summary - Newser
Is Neuphoria Therapeutics Inc. stock a growth or value playFree Fundamental + Technical Hybrid Stock Tips - Newser
Why Neuphoria Therapeutics Inc. stock attracts strong analyst attentionFree Day Trading Signals With High Precision - Newser
Published on: 2025-07-30 03:10:38 - metal.it
How to integrate Neuphoria Therapeutics Inc. into portfolio analysis toolsFundamental Analysis for Value Stock Selection - Newser
Will Neuphoria Therapeutics Inc. stock benefit from interest rate changesEquity Forecast with Predictive AI Screener - Newser
What makes Neuphoria Therapeutics Inc. stock price move sharplyTrading Volume Anomaly Summary and Insight - Newser
How high can Neuphoria Therapeutics Inc. stock price go in 2025Real Stock Picks With Setup Verification - Newser
Published on: 2025-07-28 23:50:41 - beatles.ru
Published on: 2025-07-28 06:17:17 - jammulinksnews.com
What are analysts’ price targets for Neuphoria Therapeutics Inc. in the next 12 monthsOutstanding growth strategies - jammulinksnews.com
What institutional investors are buying Neuphoria Therapeutics Inc. stockGrow your wealth steadily and securely - jammulinksnews.com
Is Neuphoria Therapeutics Inc. stock overhyped or has real potentialMarket-beating returns - jammulinksnews.com
Will Neuphoria Therapeutics Inc. stock split in the near futureConsistent triple returns - jammulinksnews.com
Neuphoria Therapeutics Inc. Stock Analysis and ForecastStrongest growth potential - PrintWeekIndia
Is Neuphoria Therapeutics Inc. a good long term investmentBreakthrough wealth creation - PrintWeekIndia
What drives Neuphoria Therapeutics Inc. stock priceTriple-digit returns - Autocar Professional
What analysts say about Neuphoria Therapeutics Inc. stockUnstoppable trading performance - Autocar Professional
Published on: 2025-07-22 18:43:03 - jammulinksnews.com
Rubrik Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Sal Automotive Limited (539353) to Launch New Product LineConsistent triple-digit returns - jammulinksnews.com
Rich Universe Network Limited (530271) Sees Unusual Trading VolumeMarket-beating performance - jammulinksnews.com
What analysts say about Ocean Power Technologies Inc. stockHigh-octane financial growth - jammulinksnews.com
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
There is no financial data for Neuphoria Therapeutics Inc (NEUP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):